Please Note: If your preferred location shows no appointments for a particular type of vaccine, please check back as we open appointments as vaccine supply becomes available.
Respiratory syncytial virus, or RSV leads to approximately 60,000-120,000 hospitalizations among adults 65 and older every year. Arexvy is a single-dose vaccine approved for the prevention of lower respiratory tract disease caused by RSV.
RSV is a common respiratory virus that usually causes mild, cold-like symptoms. Most people recover from RSV in 1-2 weeks, but it can cause serious illness. Older adults and infants are more likely to develop severe RSV.
Adults 60 years of age and older may receive a single dose of RSV vaccine.
To learn more, visit: https://www.cdc.gov/rsv/index.html